TY - JOUR
T1 - Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease
AU - Tefferi, Ayalew
AU - Zellers, Robin A.
AU - Banks, Peter M.
AU - Therneau, Terry M.
AU - Colgan, Joseph P.
PY - 1990/12
Y1 - 1990/12
N2 - Histologic and paraffin immunohistologic studies were carried out on 32 patients with lymphocyte-predominance Hodgkin's disease (LPHD) seen from 1970 through 1982. While nodular histology was accurately predictive of B-cell phenotype (Leu M1-/L26+), diffuse histology corresponded to either B-cell or Hodgkin's (Leu M1+/L26-) phenotype, not invariably predictable even when attention was paid to subtle paragranuloma cytology. Clinical characteristics were compared between histologic (diffuse v nodular) and immunophenotypic (Leu M1+/L26-, Hodgkin's phenotype, v Leu M1-/L26+, B-cell phenotype) subgroups. Ten patients have since died, and the median follow-up of the living patients was 14 years (range, 6 to 31). Of the several clinical parameters compared, only axillary nodal presentation was strongly associated with both B-cell phenotype and nodular histology, while male predominance related more to B-cell phenotype than nodular histology. No significant difference in overall survival or relapse rate was apparent among either the histologic or the immunophenotypic subgroups. However, very late but salvageable relapses were associated with nodular histology. The incidences of secondary malignancies and death from Hodgkin's disease (HD) were also comparable between the subgroups. Although differences in clinical presentation may exist, neither the histologic nor the immunophenotypic subcategories of LPHD could be demonstrated to correlate with differences in clinical outcome.
AB - Histologic and paraffin immunohistologic studies were carried out on 32 patients with lymphocyte-predominance Hodgkin's disease (LPHD) seen from 1970 through 1982. While nodular histology was accurately predictive of B-cell phenotype (Leu M1-/L26+), diffuse histology corresponded to either B-cell or Hodgkin's (Leu M1+/L26-) phenotype, not invariably predictable even when attention was paid to subtle paragranuloma cytology. Clinical characteristics were compared between histologic (diffuse v nodular) and immunophenotypic (Leu M1+/L26-, Hodgkin's phenotype, v Leu M1-/L26+, B-cell phenotype) subgroups. Ten patients have since died, and the median follow-up of the living patients was 14 years (range, 6 to 31). Of the several clinical parameters compared, only axillary nodal presentation was strongly associated with both B-cell phenotype and nodular histology, while male predominance related more to B-cell phenotype than nodular histology. No significant difference in overall survival or relapse rate was apparent among either the histologic or the immunophenotypic subgroups. However, very late but salvageable relapses were associated with nodular histology. The incidences of secondary malignancies and death from Hodgkin's disease (HD) were also comparable between the subgroups. Although differences in clinical presentation may exist, neither the histologic nor the immunophenotypic subcategories of LPHD could be demonstrated to correlate with differences in clinical outcome.
UR - http://www.scopus.com/inward/record.url?scp=0025694960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025694960&partnerID=8YFLogxK
U2 - 10.1200/JCO.1990.8.12.1959
DO - 10.1200/JCO.1990.8.12.1959
M3 - Article
C2 - 2230888
AN - SCOPUS:0025694960
SN - 0732-183X
VL - 8
SP - 1959
EP - 1965
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -